65 results about "Immune status" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

The invention provides a hospital infection propagation path tracing method based on multi-source data fusion, and belongs to the technical field of infection propagation paths in hospitals, and the method comprises the steps: building a data set through collecting hospital multi-source infection monitoring data, constructing a multi-layer network propagation model comprising physical contact, spatial proximity and time co-occurrence, and carrying out the tracing of the multi-source infection propagation path. Community detection is carried out by using a random block model, infection propagation path identification is converted into graph coloring problem solving, an individual behavior heterogeneity model is established, and SEIR model propagation parameters are corrected by fusing individual characteristic parameters such as the immune state of a patient and the protection level of medical staff; a propagation situation awareness model based on a hybrid expert mechanism is adopted to optimize propagation parameter estimation, and a propagation parameter weight coefficient is obtained through a game optimization mechanism and Nash equilibrium solution for iterative optimization. And finally, outputting a high-confidence infection propagation path sequence and a propagation source positioning result by adopting a propagation path backtracking algorithm in combination with spatial-temporal correlation analysis.

The invention relates to a method for detecting Breg cells and Tfh cells in a chest adenoma tissue microenvironment, which comprises the following steps of: coupling quantum dots with a specific antibody, dyeing a chest adenoma tissue slice sample, and specifically connecting the specific antibody with antigens on the Breg cells and / or Tfh cells in the slice sample cells, so as to quantify or position the Breg cells and / or Tfh cells by the quantum dots. According to the method disclosed by the invention, the existing multicolor immunofluorescence technology is improved, and a secondary antibody dyeing link is omitted by using a method of carrying the antibody by the quantum dots, so that the efficiency is improved; the quantum dots are used for replacing fluorescent dye, direct marking of tissue slices can be achieved, local positioning of Breg cells and Tfh cells in a thymoma tumor microenvironment is achieved, and biological behaviors of the Breg cells and the Tfh cells can be determined conveniently; the immune condition can be evaluated by detecting the ratio condition of Breg / Tfh cells in the breast adenoma tumor microenvironment of a patient in vitro.

Systems and methods to assess immune receptor sequences can incorporate a language model to yield embedded representations and classification of immune status. Classification systems and method can include assessment of embedded immune receptor sequence representations that account for isotype or V(D)J gene segment selection. Systems and methods to assess immunity status can incorporate one or more classifiers to predict immune status.

The invention relates to a kit and a method for simultaneously detecting IL-6, IL-21 and T cell CD4 surface molecules in lymphatic tissue, and belongs to the field of biomedicine. The kit comprises a quantum dot marked with an IL-6 antibody, a quantum dot marked with an IL-21 antibody and a quantum dot marked with a CD4 antibody. The antibodies marked by the quantum dots are specifically combined with antigens in lymphatic tissues respectively; the CD4T cells have the capacity of secreting IL-6 and IL-21, and the mutual relation between the CD4T cells and IL-6 and IL-21 reflects the tissue immunocompetence. The invention provides a kit for simultaneously detecting IL-6, IL-21 and T cell surface molecules in lymphatic tissues, which positions the spatial relationship between two cell factors and T cells, calculates and analyzes corresponding fluorescence intensity and evaluates immune conditions. The kit has the advantages of high fluorescence intensity, accurate detection result, wide spectrum selection, wide applicability, stable fluorescence structure, long preservation time, high sensitivity, good specificity and the like.

The invention relates to the field of medical diagnosis, and particularly discloses a biomarker combination and a kit for HIV / Mtb co-infection immune state evaluation and clinical diagnosis and application of the biomarker combination and the kit. Multi-factor detection is carried out on peripheral blood samples of an HIV infected person, an Mtb infected person and an HIV / Mtb co-infected person, Lasso regression screening is adopted to obtain cell factors closely related to HIV / Mtb co-infection, such as FGF-2, IL-7, I-309, TNF-alpha, MMP-1 and MMP-7, and a multi-factor diagnosis model is constructed. The model shows high sensitivity, specificity and AUC value in a training set and a test set, can effectively distinguish HIV individual infection and HIV / Mtb co-infection individuals, and is especially suitable for diagnosis of patients with low CD4 + T cell level. The marker combination provided by the invention and the kit prepared from the marker combination can be used as a supplement of an immunological detection method, and a new technical means is provided for clinical diagnosis and immune state evaluation of HIV / Mtb co-infection.

The invention belongs to the technical field of biomolecular markers, and particularly relates to a cross-animal general skeleton-derived hematopoietic stem cell marker gene set and a screening method thereof. According to the invention, a bone-derived hematopoietic stem cell marker gene set universal across animal categories is constructed for the first time, and the bone-derived hematopoietic stem cell marker gene set comprises at least five of Cdc42, Cbx, Tfam, Denr, Mcts1, Ak2, Ruvbl, Ahcy, Nna and Vdac; the hematopoietic stem cell marker gene set is obtained through cross-species homologous gene screening, the defect that a traditional vertebrate marker has no orthohomology in invertebrates is overcome, accurate recognition of HSC in shells is achieved, the hematopoietic stem cell marker gene set has species universality and cell specificity, the immune state of aquatic animals can be evaluated, disease-resistant breeding can be guided, and the application prospect is wide. And molecular evidence is provided for analyzing an evolution path of a hematopoietic system from invertebrates to vertebrates.

The invention relates to application of plasma IL-1Ra as a biomarker in prognosis of sepsis in children. The prognosis product is used for measuring the IL-1Ra level on the first day after sepsis diagnosis, and is used for evaluating the immune state and prognosis of sepsis patients. The invention discloses the potential of IL-1Ra as a sepsis immune response regulatory factor, and the increased level of IL-1Ra can be used as a predictive marker for clinical outcome of sepsis, and especially has important clinical significance in children with abnormal immune function. The discovery provides a new biomarker for early diagnosis, prognosis evaluation and treatment of sepsis, and provides an important basis for clinical management.

The present application relates to the field of medical immunology technology, and more particularly to biomarkers and their application in the assessment of liver damage in end-stage liver disease. In the present application, the proportion of CCR7+CD8+ T cells in CD8+ T cells is used as a marker for the assessment of liver damage in end-stage liver disease, which can reflect the liver immune status of end-stage liver disease, especially the assessment of the degree of liver damage, has high specificity and sensitivity, and provides a scientific basis for the development of clinical individualized treatment plan, and has good practical application value. At the same time, while reflecting the liver damage process of the patient, it can also reflect the immune status of the patient's liver, and can provide certain theoretical basis for slowing down the disease progression of subsequent biliary atresia and other end-stage liver disease patients with liver damage.

The present invention relates to a composition for diagnosing immunodeficiency or a method for providing information for diagnosis thereof. By using the composition and the method according to one aspect, it is possible to simply and effectively diagnose immune-deficient conditions such as immunosuppression or immune paralysis.

The invention discloses a hematologic tumor diagnosis and treatment primer group, a kit and application. The primer group comprises a first primer group and / or a second primer group, the first primer group is used for amplifying IGH, IGDH, IGK and IGL; the first primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, the second primer group is used for amplifying TRB V-J, TRB D-J, TRG and TRD, after the primer groups amplify and rearrange sequences, the positive detection of clinical samples can be remarkably improved, the obtained CDR3 sequence can be used for clinical monitoring and can independently evaluate an immune group library of each patient, the immune state of an individual can be accurately reflected, the change condition of tumor cells of the patient can be dynamically monitored, and the clinical detection efficiency can be improved. And the method has good reliability and repeatability.

The invention provides a lung cancer microenvironment ecological characteristic detection and curative effect evaluation system, and relates to the technical field of lung cancer prognosis evaluation, and the system comprises a reading module which is used for reading slice information of a subject; the boundary construction module is used for constructing a region boundary according to the tumor region in the slice information; identifying tumor infiltrating lymphocytes (TILs for short) from the slice information, and determining the distribution type of the tumor infiltrating lymphocytes in combination with the distribution characteristics and the region boundary of the tumor infiltrating lymphocytes; the method comprises the following steps of: obtaining slice information, identifying a three-level lymphatic structure (TLS for short) from the slice information, and determining a distribution type of the three-level lymphatic structure in combination with distribution characteristics and a region boundary of the three-level lymphatic structure; and the evaluation module is used for performing prognosis effect prediction on the subject based on the distribution type of tumor infiltration lymphocytes and the distribution type of the three-level lymphatic structure, deeply analyzing the immune condition of a tumor micro-environment (TME for short), and improving the accuracy of prognosis evaluation.

Disclosed are methods and agents for predicting response to therapy, immune status and / or disease progression. More particularly, disclosed are methods, agents and kits for analyzing cellular distribution of PD-L2, including its nuclear localization, for stratifying a patient as a likely responder or non-responder to a therapy, for managing treatment of a patient with a therapy, for monitoring a disease in a patient following treatment with a therapy, for determining the status of a disease and / or for determining the immune status of a patient.

The invention discloses a hepatocellular carcinoma prognosis and treatment adaptability evaluation model based on mRNA vaccine antigen and a construction method. The method comprises the following steps: firstly, analyzing gene expression difference between normal tissues and hepatocellular carcinoma tumors, understanding mutation and genome structure change of hepatocellular carcinoma patients, and then further selecting genes related to the infiltration level of antigen presenting cells from abnormally expressed genes and mutant genes, and the genes having a significant relationship with the overall lifetime and disease-free lifetime of the patient, so as to obtain candidate mRNA vaccine neoantigen targets. Based on the expression level of the target, immunotyping is performed on the patient, and the patient population suitable for the mRNA vaccine is evaluated. Meanwhile, the relationship between the expression level of the target spot and the prognosis of the patient is quantified, so that the probability value that the total survival time of the hepatocellular carcinoma patient reaches 3 years and 5 years is predicted. According to the invention, the hepatocellular carcinoma treatment resistance and tumor immune state can be objectively and accurately evaluated, and the prediction accuracy of hepatocellular carcinoma treatment prognosis is improved.

The present invention relates to a biomarker HLA-DOA for sepsis-related diseases and a use thereof. The present invention provides a use of HLA-DOA or an active fragment or functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction and / or treatment regimen selection of sepsis-related diseases in a subject.

This invention discloses a prognostic and therapeutic suitability assessment model for hepatocellular carcinoma (HCC) based on mRNA vaccine antigens, and its construction method. First, the differences in gene expression between normal tissues and HCC tumors are analyzed to understand the mutations and genomic structural changes in HCC patients. Then, genes related to the level of antigen-presenting cell infiltration, as well as genes significantly related to overall survival and disease-free survival, are further selected from anomalously expressed and mutated genes to obtain candidate mRNA vaccine neoantigen targets. Based on the expression levels of these targets, patients are immunophenotyped to assess the patient population suitable for mRNA vaccines. Simultaneously, the relationship between target expression levels and patient prognosis is quantified to predict the probability of HCC patients achieving 3-year and 5-year overall survival. This invention can objectively and accurately assess treatment resistance and tumor immune status in HCC, improving the predictive accuracy of HCC treatment prognosis.

The present invention belongs to the field of mass spectrometry flow cytometry technology, specifically a detection kit and application for evaluating the purity of NK cell culture using mass spectrometry flow cytometry technology. The present invention discloses a kit for detecting the immune status of human NK cells. The kit can be used to monitor changes in the immune status of the human body and evaluate the purity of its NK cell culture. Based on a specific or unified culture method, the difference in the purity of NK cell culture in samples is evaluated, thereby reducing the overactivation of NK cells. For samples with low NK cell culture purity, the types of additives or culture medium components are controlled to be added, and the NK cells are specifically purified and activated, thereby reducing the difference between samples with high-purity NK cell culture and samples with low-purity NK cell culture. 37 antibodies can be used to quickly and accurately perform in-depth analysis of immune cells in peripheral blood and evaluate the purity of NK cell culture by collecting peripheral blood intravenously on a mass spectrometry flow cytometer platform.

The invention discloses a 15-antibody combination for accurately detecting a mouse tissue immune cell subset and application of the 15-antibody combination. Aiming at the problems of large fluctuation and instability of detection results caused by adjustment of voltage and fluorescence compensation during detection by a flow cytometer and different processing modes during result analysis, the antibody combination disclosed by the invention takes monoclonal antibodies CD45, CD3, CD4, CD8, CD19, B220, Ly-6C, Ly-6G, MHC-II, CD11c, CD49b, CD62L, CD44 +, PD-1 and PD-L1 as effective components, and a stable and standard detection method for mouse tissue immune cell subsets is established. The method can analyze the proportion, number and distribution of various immune cells (T cells, B cells, NK cells, dendritic cells, mononuclear cells and granulocytes) in spleen, lung, liver, brain or kidney tissues of mice, can reflect the immune state of the mice and evaluate the immunosuppression state, and can be applied to the fields of disease models, drug evaluation, vaccine development and the like.

Systems and methods for evaluating peptide sequences can be incorporated into language models to provide latent representations. Biological characteristics can be predicted based on the latent representations of peptide sequences. Systems and methods for evaluating immune status can incorporate one or more models and classifiers for predicting healthy status. Various systems and methods can predict whether an individual has an active immunological response. Various systems and methods can predict whether an individual has or has had a particular type of immunological response, such as a pathogenic infection, vaccination, or immunological disorder.

Circulating free RNA (cfRNA) is used for monitoring status and / or treatment response for neural tumors, and especially glioma, glioblastoma, and neuroblastoma. Particularly preferred cfRNAs include those that encode a marker that is specific to a neural tumor, but also markers that are specific to DNA repair status and / or immune status.

The invention relates to a method for detecting an immune state in thymus hyperplasia tissue in an EB (Epstein-Barr) virus infection state, which comprises the following steps of: constructing a kit comprising a quantum dot coupled CD19 antibody and a quantum dot coupled CD86 antibody; after the conjugate of the quantum dot and the specific antibody is specifically combined with an antigen on a B cell in a tissue slice sample, marking of the quantum dot on a costimulatory molecule on the surface of the B cell is realized; and judging the immune state of the thymus hyperplasia tissue according to a marking result. The quantum dot coupling antibody can be directly combined with an antigen on a tissue slice to realize direct marking of the quantum dot coupling antibody on the tissue slice, so that the B cell surface costimulatory molecules in a thymus hyperplasia tissue microenvironment are quantified and positioned, the relationship between the B cell surface costimulatory molecules and thymus hyperplasia-related autoimmune diseases is determined, and the accuracy and the sensitivity of the B cell surface costimulatory molecules in the thymus hyperplasia tissue microenvironment are improved. The immune state of the thymus hyperplasia tissue microenvironment can be evaluated, and autoimmune diseases can be predicted.

The present invention relates to a sepsis-related disease biomarker HLA-DQA and the use thereof. Provided in the present invention is the use of HLA-DQA or an active fragment and functional fragment thereof in the preparation of a product for early diagnosis, risk assessment, immune status assessment, prognosis prediction, and / or treatment regimen selection of a sepsis-related disease in a subject.

The invention provides a pathogen immune lineage evaluation method based on high-throughput antibody epitope spectrum detection data. The pathogen immune lineage evaluation method comprises the following steps: data preparation: obtaining sequencing data of an antigen epitope library and sample sequencing data after co-immunoprecipitation of a biological sample and library incubation; data preprocessing: performing quality control on all sequencing data; comparing and counting data: constructing a reference library index, comparing the indexes, and counting read segments of the disease epitope peptide segments; identifying epitope peptide fragments which are remarkably enriched in the sample; calculating a calibration coefficient; and calculating the enrichment immunocharacterization characteristics of the pathogens and judging whether the pathogens are positive immunoreactions or not. According to the EPIC scoring evaluation method, thousands of virus site information can be efficiently processed and summarized, the immune state of an individual for various pathogens is accurately evaluated, key information is extracted from high-throughput detection data, the binding condition of an antibody and an antigen epitope is accurately recognized, and a detection result is visually presented in an image visualization mode.

The invention belongs to the technical field of postoperative immune state evaluation of a patient suffering from thymoma, and particularly relates to a postoperative immune state monitoring and prognosis evaluation method for the patient suffering from thymoma. According to the method, the immune states of the patient are dynamically tracked by accurately monitoring and evaluating the immune states of the patient in different postoperative periods, the recovery condition of the postoperative immune function of the patient can be reflected by collecting blood samples of the patient in different postoperative periods and detecting the proportion of T cell subsets in the blood samples, and meanwhile, the recovery condition of the postoperative immune function of the patient can be accurately evaluated. According to the method, sample parameters are screened, classified and evaluated, invalid sample parameters are effectively removed, the accuracy of evaluating the immune state of the patient is improved, and therefore a more reliable evaluation basis is provided for doctors, the doctors are helped to formulate a more scientific and reasonable treatment scheme, and in addition, the treatment efficiency is improved. The prognosis risk level can be determined according to the immune deviation amount of the patient, and a more reliable prognosis evaluation basis is provided for doctors.

The present invention relates to a biomarker group of B cells and a use thereof. According to the present invention, a single-cell transcriptome analysis technology is used, and by analyzing single-cell gene expression profiles of B cells in cancerous and adjacent non-cancerous tissues of cancer patients, B cell subsets capable of reflecting a body's tumor immune status, namely, naïve B cells expressing genes Cd83 and Irs2, are isolated and characterized. Moreover, further studies identified that new characteristic genes Cd83 and Irs2 expressed by the cell subsets and the relationship between the proportion of naïve B cells and tumor prognosis can be used for diagnosis and monitoring of tumor prognosis, and as novel targets for tumor immunotherapy.

The present invention belongs to the technical field of traditional Chinese medicine preparations, and discloses a process for preparing an oral spray for inhibiting oral pathogens, comprising a tank body, a tank cover provided on the top of the tank body, a discharge pipe provided on the bottom of the tank cover, a control valve provided on the discharge pipe, a first motor fixedly mounted on the top of the tank cover, an output end of the first motor fixedly connected to a rotating shaft, one end of the rotating shaft extends through the tank cover to the interior of the tank body, and a first movable plate fixedly connected to the outer surface of the rotating shaft. Traditional Chinese medicine has a variety of active ingredients, such as flavonoids, volatile oils and polysaccharides, etc. These ingredients have broad-spectrum antibacterial, anti-inflammatory and therapeutic effects, providing a safer and more effective option for oral rehabilitation treatment. By comprehensively considering factors such as microbial composition, immune status and changes in oral mucosa, and by in-depth research on the regulatory effect of traditional Chinese medicine sprays on the oral microenvironment, a more comprehensive and accurate solution can be provided for post-implantation rehabilitation treatment, which is easy to use.

The present application provides methods of identifying the immune status of a subject, and use of a reagent for detecting IL-1R2 levels in a sample from a subject in the manufacture of a product for identifying the immune status of the subject. The present application also provides antibodies that bind human IL-1R2 and uses thereof, and hybridoma cells that produce antibodies that bind human IL-1R2 and uses thereof.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

This invention discloses a method and system for assessing immune age and status using transcriptomics. The invention provides the application of a gene composition highly correlated with age in assessing immune age and status. By utilizing the actual age of the user being tested and the expression levels of the aforementioned gene composition in their peripheral blood mononuclear cell transcriptome, immune age, immune rings, and immune aging index are analyzed to assess immune status. For users whose immune status deviates from the normal range, further classification of their immune status can be determined. This invention employs a machine learning-based approach to effectively extract immune age information from peripheral blood mononuclear cell transcriptome sequencing data, enabling a comprehensive assessment of immune status and providing effective guidance for health status.